肾综合征出血热早期凝血六项检测及应用肝素的临床意义

Detection on Six Items of Blood Coagulation for Hemorrhagic Fever with Renal Syndrome and Clinical Analysis of Using Heparin Sodium

目的探讨小剂量肝素对肾综合征出血热(HFRS)的临床意义。方法将两组HFRS发热期患者在入院当天均做凝血六项检测,其中一组(肝素组)每天用5%的葡萄糖250m l加肝素6250单位(50mg)静滴一次,4天为一疗程。其他治疗两组均按HFRS常规治疗。结果肝素组血小板(PLT)和纤维蛋白原(FIB)的非正常参考值指标均高于非肝素组(P<0.01),提示肝素组病情重于非肝素组,而肝素组死亡率(5.8%)却低于非肝素组(8.2%)。结论HFRS患者早期应用小剂量肝素,对减少病理损伤,及时纠正高凝状态,防止血栓形成,降低病死率具有临床意义。

Objective To discuss the clinical significance of heparin sodium for hemorrhagic fever with renal syndrome （HFRS）. Methods Six items of blood coagulation were detected at the same day when HFRS patients of two groups enter the hospital. One group （heparin sodium group） was treated by heparin sodium （50mg） with glucose （5%, 250ml） through intravenous injection once a day, with 4 days as a course of treatment. Other routine treatments were the same for the two groups. Results The non -normal values for blood platelet （PLT） and fibrinogen （FIB） of heparin sodium group were larger than that of non- heparin sodium group （P 〈0.01 ） , indicating that the condition of heparin sodium group was worse than that of non - heparin sodium group. However, the death rate of heparin sodium group （5.8%） were lower than that of non - heparin sodium group （8.2%）. Conclusion Early treatment with low dosed heparin sodium for HFRS is clinically significant since it may decrease pathology damaging, rectify highly coagulative state, prevent thrombosis and hence decrease the death rate.